Study guide
14.4 Tubulointerstitial & Inherited Renal Diseases
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
14.4 Tubulointerstitial & Inherited Renal Diseases
Key Takeaways Explain This Topic AI
Acute interstitial nephritis (AIN) is driven by drug-induced hypersensitivity (>75% of cases; NSAIDs, penicillins, cephalosporins, ciprofloxacin, PPIs, allopurinol); the classical triad of fever, rash, and arthralgia is present in only 10–30%, while sterile pyuria and white cell casts are hallmark urinary findings.
Management of AIN requires immediate withdrawal of the offending drug; if serum creatinine fails to improve within 5–7 days, a prompt course of oral corticosteroids should be initiated to avert permanent chronic interstitial fibrosis.
Renal tubular acidosis (RTA) presents as normal anion gap (hyperchloraemic) metabolic acidosis: Type 1 (distal defect in intercalated cell H+ secretion, urine pH >5.5 despite acidaemia, hypokalaemia, nephrocalcinosis/stones), Type 2 (proximal bicarbonate wasting, urine pH <5.5 when bicarb low, hypokalaemia, Fanconi syndrome), and Type 4 (hypoaldosteronism, hyperkalaemia, urine pH <5.5).
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 (chromosome 16, 85%, earlier ESRD) or PKD2 (chromosome 4, 15%); extra-renal features include hepatic cysts (70–80%), intracranial berry aneurysms (screening MRA if positive family history of SAH), mitral valve prolapse, and diverticulosis; tolvaptan (vasopressin V2 antagonist) slows cyst growth.
Alport syndrome is an X-linked defect in the alpha-5 chain of type IV collagen (COL4A5) presenting with microscopic haematuria, high-frequency sensorineural deafness, anterior lenticonus, and 'basket-weave' lamina densa on electron microscopy; ~3–5% develop de novo anti-GBM disease post-renal transplant.
Last updated: September 2026
Tubulointerstitial nephropathies and inherited nephrogenetic disorders constitute a significant source of diagnostic and management questions in MRCP(UK) Part 1. A firm grasp of drug-induced hypersensitivity mechanisms, acid-base physiology across the collecting duct, genetic loci, and targeted therapies is critical.
1. Acute Interstitial Nephritis (AIN)
Acute interstitial nephritis is an immunologically mediated inflammatory condition characterized by interstitial oedema and inflammatory cellular infiltration of the renal interstitium with secondary tubular damage ( tubulitis ). Over 75–85% of cases are secondary to adverse drug hypersensitivity reactions.
Culprit Medications
Antibiotics: Penicillins (amoxicillin, ampicillin, flucloxacillin), cephalosporins, fluoroquinolones ( ciprofloxacin ), sulfonamides (co-trimoxazole), and rifampicin.
Proton Pump Inhibitors (PPIs): Omeprazole , lansoprazole, pantoprazole. Key exam pearl: PPI-induced AIN characteristically exhibits an insidious, delayed onset, frequently developing weeks to months after starting the drug, often without any systemic hypersensitivity symptoms.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, naproxen, celecoxib. Uniquely, NSAIDs can cause concurrent podocyte foot process effacement, presenting as combined AIN and full-blown nephrotic-range proteinuria (minimal change-like picture) .
Other Common Culprits: Allopurinol, thiazide and loop diuretics, immune checkpoint inhibitors (anti-PD-1 / PD-L1 monoclonal antibodies: nivolumab, pembrolizumab).
Non-Drug Aetiologies: Autoimmune systemic diseases (sarcoidosis with non-caseating granulomas, Sjögren's syndrome, systemic lupus erythematosus), infections (Legionella, leptospirosis, CMV, EBV), and Tubulointerstitial Nephritis with Uveitis ( TINU syndrome , seen primarily in adolescents and young women).
Clinical Presentation & Diagnostic Evaluation
Classical Triad: Fever, maculopapular cutaneous rash, and arthralgia . Crucially, this complete triad is present in only 10–30% of biopsy-proven cases . Its absence must never rule out AIN!
Urinalysis & Microscopy:
Sterile Pyuria: Leukocyturia without bacterial bacteriuria on standard culture.
White Blood Cell (WBC) Casts: Highly specific for acute interstitial inflammation in the absence of active pyelonephritis.
Proteinuria: Typically mild to moderate (sub-nephrotic, < 1 g/24 hours), except in NSAID-induced AIN.
Microscopic Haematuria: Present in up to 80% of cases.
Urinary Eosinophils: Stained via Hansel or Wright stain. While historically tested, urinary eosinophil testing has poor sensitivity and specificity and is no longer recommended by international guidelines to confirm or exclude AIN.
Definitive Diagnosis: Renal Biopsy is the diagnostic gold standard, demonstrating diffuse interstitial oedema, interstitial infiltration by T-lymphocytes, monocytes, macrophages, plasma cells, and eosinophils, accompanied by invasion of the tubular basement membrane (tubulitis).
Therapeutic Management
Immediate Drug Withdrawal: Prompt cessation of the offending medication is the single most critical therapeutic intervention.
Corticosteroid Therapy: If serum creatinine fails to show objective improvement within 5–7 days following drug withdrawal, initiate oral corticosteroids ( oral prednisolone 1 mg/kg/day , typically 40–60 mg daily for 2–3 weeks, followed by a taper over 4–6 weeks). Early initiation of steroids significantly reduces the risk of irreversible chronic interstitial fibrosis and permanent loss of GFR.
2. Renal Tubular Acidosis (RTA)
Renal tubular acidosis comprises a clinical group of transport defects that cause normal anion gap (hyperchloraemic) metabolic acidosis ([Na⁺] - [Cl⁻ + HCO₃⁻] = 8–12 mmol/L) in the presence of relatively preserved glomerular filtration.
Comparative Physiology of RTA Types 1, 2, and 4
Feature Type 1 (Distal RTA) Type 2 (Proximal RTA) Type 4 (Hyperkalaemic RTA)
Primary Defect Impaired H⁺ secretion by α-intercalated cells in medullary collecting duct Impaired HCO₃⁻ reabsorption in proximal convoluted tubule Aldosterone deficiency or resistance at cortical collecting duct
Minimum Urine pH Fundamentally > 5.5 (cannot acidify urine even during severe acidaemia) < 5.5 when plasma HCO₃⁻ is low (distal acidification intact) < 5.5 (distal H⁺ pumps work, but NH₄⁺ buffer is deficient)
Serum Potassium Hypokalaemia (distal K⁺ wasting) Hypokalaemia (distal delivery of Na⁺ and HCO₃⁻ wastes K⁺) Hyperkalaemia (pathognomonic hallmark)
Nephrocalcinosis & Stones Frequent (bilateral calcium phosphate stones due to high urine pH, hypercalciuria, hypocitraturia) Absent (urine can be acidified, urinary citrate excretion is normal) Absent
Associated Features Systemic osteomalacia / rickets, sensorineural deafness (genetic forms) Fanconi Syndrome (glucosuria with normal blood sugar, phosphaturia, aminoaciduria, hypouricaemia) Mild acidosis; hyperkalaemia out of proportion to GFR reduction
Common Aetiologies Autoimmune: Sjögren's syndrome , SLE, rheumatoid arthritis; Amphotericin B, lithium Multiple myeloma (light chains), Wilson's disease, cystinosis, tenofovir , expired tetracyclines Diabetic nephropathy (hyporeninaemic hypoaldosteronism), Addison's, ACEi/ARBs, spironolactone, trimethoprim
Diagnostic Test Ammonium chloride (NH₄Cl) challenge test: urine pH remains > 5.3 Sodium bicarbonate infusion test: fractional excretion of HCO₃⁻ > 15% Positive urinary net charge ([Na⁺ + K⁺] - Cl⁻ > 0) with hyperkalaemia
Treatment Oral sodium bicarbonate or potassium citrate (corrects both acidosis and hypokalaemia) High-dose oral bicarbonate (large doses required due to urinary wasting), thiazides Low-potassium diet, loop diuretics (furosemide), oral fludrocortisone in primary deficiency
Urine Net Charge (Anion Gap): In normal anion gap metabolic acidosis, the kidney should increase ammonium (NH₄⁺) excretion paired with chloride (Cl⁻). The urinary net charge ([Na⁺ + K⁺] - Cl⁻) estimates urinary ammonium. In GI bicarbonate loss (diarrhoea), the urinary net charge is negative (normal renal response). In distal RTA (Type 1 and Type 4), ammonium excretion is impaired, resulting in a positive urinary net charge .
3. Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD is the most common monogenic cause of end-stage renal disease worldwide, affecting approximately 1 in 400 to 1 in 1,000 live births.
Molecular Genetics
PKD1 Gene Mutation (~85% of cases): Located on chromosome 16p13.3 . Encodes polycystin-1 , a high-molecular-weight integral membrane glycoprotein localized to primary cilia that acts as a mechanoreceptor. Patients with PKD1 mutations exhibit more severe disease, earlier onset of hypertension, larger kidney volumes, and earlier ESRD (median age ~53–58 years ).
PKD2 Gene Mutation (~15% of cases): Located on chromosome 4q21 . Encodes polycystin-2 , a calcium-permeable transient receptor potential (TRPP2) cation channel. Clinically milder phenotype, with later onset of hypertension and deferred ESRD (median age ~74 years ).
Pathophysiological Cascade: Disrupted ciliary polycystin signalling reduces intracellular calcium and paradoxically upregulates intracellular cyclic adenosine monophosphate (cAMP) . High cAMP activates protein kinase A, driving aberrant tubular epithelial proliferation and CFTR-mediated transepithelial fluid secretion, producing progressively expanding, fluid-filled cysts.
Clinical Manifestations
Renal: Bilateral massive nephromegaly; early hypertension (intra-renal vascular stretching stimulates local RAAS hyperactivation before eGFR declines); bilateral flank/loin pain; macroscopic haematuria (cyst rupture into collecting system); recurrent cyst infections / pyelonephritis (requires lipid-soluble antibiotics that penetrate cyst walls, such as ciprofloxacin or co-trimoxazole); and nephrolithiasis (uric acid and calcium oxalate stones in 20%).
Extra-Renal Manifestations:
Polycystic Liver Disease (Hepatic Cysts): The most common extra-renal feature, found in > 70–80% of patients by age 40. Hepatic synthetic function remains completely normal; symptoms arise purely from massive hepatomegaly (abdominal distension, early satiety).
Intracranial Berry Aneurysms: Located within the Circle of Willis. Present in 8–12% of all ADPKD patients, rising to 20–25% in those with a positive family history of intracranial aneurysm or subarachnoid haemorrhage (SAH). Rupture causes catastrophic SAH.
Screening Guidelines: Routine unselected screening is not recommended. Targeted screening with non-contrast Magnetic Resonance Angiography (MRA) is strictly indicated for: (a) family history of intracranial aneurysm or SAH; (b) prior intracranial aneurysm rupture; (c) high-risk professions (e.g. airline pilots, commercial divers); or (d) prior to major elective surgery.
Cardiovascular: Mitral valve prolapse (present in up to 25%), aortic root dilatation, tricuspid regurgitation, and thoracic/abdominal aortic aneurysms.
Gastrointestinal: Colonic diverticular disease (significantly increased risk of diverticulitis and colonic perforation, especially post-transplant) and abdominal wall/inguinal hernias.
Diagnosis: Pei-Ravine Ultrasound Criteria
In individuals with a positive family history of ADPKD, ultrasound diagnostic criteria (Ravine criteria, modified by Pei) are stratified by age:
Age 15–39 years: At least 3 unilateral or bilateral cysts.
Age 40–59 years: At least 2 cysts in each kidney (bilateral).
Age >= 60 years: At least 4 cysts in each kidney (bilateral).
Exclusion of Disease: The complete absence of cysts on high-resolution ultrasound at age >= 30 years has a negative predictive value of > 99%, effectively excluding the diagnosis.
Disease-Modifying Therapy: Tolvaptan
Mechanism of Action: Tolvaptan is a selective oral vasopressin V2 receptor antagonist . In the collecting duct, endogenous arginine vasopressin (AVP) binds to basolateral V2 receptors, activating adenylyl cyclase and boosting intracellular cAMP. Tolvaptan competitively inhibits V2 receptors, lowering intracellular cAMP and thereby decelerating tubular epithelial cellular proliferation and fluid secretion.
Clinical Evidence & Indications (NICE TA578): In the TEMPO 3:4 and REPRISE randomized trials, tolvaptan significantly slowed the rate of total kidney volume (TKV) growth and attenuated the annual decline in eGFR. Indicated for adults with CKD stages 1–3 at baseline who demonstrate evidence of rapidly progressive disease (e.g. eGFR decline >= 3 mL/min/1.73 m² per year, or Mayo imaging classification 1C, 1D, or 1E).
Adverse Effects & Monitoring: Profound aquaresis (polyuria, polydipsia, nocturia, thirst) due to drug-induced nephrogenic diabetes insipidus. Idiosyncratic drug-induced liver injury mandates monthly liver function test (LFT) monitoring for the first 18 months of therapy, then every 3 months thereafter.
4. Alport Syndrome
Alport syndrome is an inherited disorder of type IV collagen basement membrane biosynthesis, characterized by progressive hereditary nephritis, high-frequency sensorineural deafness, and specific ocular lesions.
Molecular Genetics & Pathogenesis
Inheritance Patterns:
X-Linked Alport Syndrome (~85% of cases): Mutations in the COL4A5 gene on chromosome Xq22, encoding the alpha-5 chain of type IV collagen. Hemizygous males develop full phenotypic expression with inevitable progression to ESRD by the second to fourth decade. Heterozygous females display variable phenotypes ranging from lifelong isolated microscopic haematuria to overt renal failure (due to random X-chromosome inactivation/lyonization).
Autosomal Recessive (~15%): Mutations in COL4A3 or COL4A4 on chromosome 2.
Type IV collagen heterotrimers (specifically the alpha-3-alpha-4-alpha-5(IV) network) form the fundamental structural backbone of mature basement membranes in the glomerulus, cochlea, and anterior eye. Failure of normal heterotrimer assembly leaves the thinner, developmentally primitive alpha-1-alpha-1-alpha-2(IV) network, which is mechanically fragile and vulnerable to proteolytic degradation.
Clinical Triad
Progressive Nephropathy: Microscopic haematuria from early childhood; intermittent macroscopic haematuria precipitated by viral infections; progressive proteinuria; hypertension; and progressive decline to ESRD in early adult life in affected males.
Sensorineural Hearing Loss: Bilateral, symmetrical, progressive high-frequency sensorineural deafness. Typically absent in infancy; manifests in late childhood or early adolescence.
Ocular Abnormalities: Pathognomonic anterior lenticonus (bilateral conical protrusion of the central anterior lens capsule into the anterior chamber, causing progressive axial myopia; virtually specific to Alport syndrome), central perimacular flecks (yellow-white punctate dots surrounding the fovea), and corneal endothelial vesicles.
Histopathology
Light Microscopy: Segmental glomerulosclerosis, tubular atrophy, and prominent interstitial lipid-laden foam cells .
Electron Microscopy (Pathognomonic): Irregular thickening, thinning, and longitudinal splitting/lamellation of the lamina densa of the glomerular basement membrane, producing a classic "basket-weave" appearance .
Management & Post-Transplant Complication
Renoprotection: Early initiation of ACE inhibitors or ARBs at the first sign of microalbuminuria substantially delays progression to ESRD.
Renal Allograft Transplantation & De Novo Anti-GBM Disease: Kidney transplantation is the definitive treatment for ESRD. However, approximately 3–5% of transplanted Alport males develop de novo anti-GBM crescentic glomerulonephritis in the donor allograft. Because the recipient's native immune system was never exposed to the normal alpha-3-alpha-4-alpha-5(IV) collagen chains, it mounts a vigorous humoral immune response against the donor kidney's normal basement membrane.